Compare PubMatic Inc (PUBM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Sanofi SA — how do they compare? PubMatic Inc trades at $16.19 (market cap $736.54M), while Sanofi SA trades at $43.12 (market cap $103.41B). The key difference: Sanofi SA is far larger — about 140.4× PubMatic Inc's market cap, and Sanofi SA pays a 5.65% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| PUBM | SNY | |
|---|---|---|
Market Cap | $736.54M | $103.41B |
Sector | Technology | Health |
52-Week High | $17.78 | $52.34 |
52-Week Low | $6.28 | $41.33 |
Enterprise Value | $639.67M | $123.44B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PUBM trades at $16.29, down 1.27% on the day, with a bullish technical signal supported by moving averages and recent crossing above the 20-day average. The company reported Q2 2026 revenue growth of 10.5% year-over-year and an EPS beat, driven by mobile app and CTV segments. Analyst consensus is strongly positive with 11 buy ratings and a $20.83 price target, implying 28% upside from current levels.
The outlook is cautiously optimistic given strong revenue momentum and AI product adoption, but negative net margins and high P/E of 132 pose valuation risks. Key catalysts include continued execution in high-margin segments and leadership transitions, while competitive pressures and macroeconomic headwinds remain concerns for sustained profitability.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
